Pacira Pharmaceuticals (PCRX) : During the past 4 weeks, traders have been relatively bearish on Pacira Pharmaceuticals (PCRX), hence the stock is down -11.87% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -7.32% relative to the S&P 500. The 4-week change in the price of the stock is -12.35% and the stock has fallen -7.16% in the past 1 week.
The stock has recorded a 20-day Moving Average of 12.08% and the 50-Day Moving Average is 14.77%.The 200 Day SMA reached 32.22%
Pacira Pharmaceuticals (NASDAQ:PCRX): After opening at $34.02, the stock dipped to an intraday low of $32.72 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $34.58 and the buying power remained strong till the end. The stock closed at $34.22 for the day, a gain of 0.59% for the day session. The total traded volume was 1,132,983. The stocks close on the previous trading day was $34.22.
Pacira Pharmaceuticals (PCRX) has been rated by 7 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $109 and the lowest price target forecast is $47. The average forecast of all the analysts is $73.57 and the expected standard deviation is $19.89.
Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is focused on the development, commercialization and manufacture of pharmaceutical products, based on its DepoFoam drug delivery technology, primarily for use in hospitals and ambulatory surgery centers. Its primary focus lies in the development of non-opioid products for postsurgical pain control. DepoFoam is basis for the companys lead product candidate, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other commercial product, DepoCyt(e), which the Company manufactures for its commercial partners, as well as its other product candidates. The Companys other product candidates include DepoMeloxicam and DepoTranexamic Acid.